

Charles N Serhan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9396884/publications.pdf>

Version: 2024-02-01

564
papers

85,926
citations

168

157
h-index

521

273
g-index

587
all docs

587
docs citations

587
times ranked

42596
citing authors

#	ARTICLE	IF	CITATIONS
1	Resolvin T-series reduce neutrophil extracellular traps. <i>Blood</i> , 2022, 139, 1222-1233.	0.6	36
2	<i>Staphylococcus aureus</i> controls eicosanoid and specialized pro-resolving mediator production via lipoteichoic acid. <i>Immunology</i> , 2022, 166, 47-67.	2.0	8
3	COVID-19 and cancer: start the resolution!. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 1-15.	2.7	5
4	E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition. <i>Seminars in Immunology</i> , 2022, 59, 101597.	2.7	30
5	Resolvin D2 and Resolvin D1 Differentially Activate Protein Kinases to Counter-Regulate Histamine-Induced [Ca ²⁺] _i Increase and Mucin Secretion in Conjunctival Goblet Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 141.	1.8	3
6	First stereoselective total synthesis of 4 <i>S</i> ,5 <i>S</i> -oxido-17 <i>S</i> -hydroxy-6 <i>E</i> ,8 <i>E</i> ,10 <i>Z</i> ,13 <i>Z</i> ,15 <i>E</i> ,19 <i>Z</i> -docosahexaenoic acid, the biosynthetic precursor of resolvins D3 and D4. <i>RSC Advances</i> , 2022, 12, 11613-11618.		
7	Periodontal Stem Cells Synthesize Maresin Conjugate in Tissue Regeneration 3. <i>Journal of Dental Research</i> , 2022, , 002203452210908.	2.5	7
8	Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions. <i>Progress in Lipid Research</i> , 2022, 86, 101165.	5.3	164
9	Signaling Pathways Used by the Specialized Pro-Resolving Mediator Maresin 2 Regulate Goblet Cell Function: Comparison with Maresin 1. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6233.	1.8	4
10	A newly synthesized 17-epi-NeuroProtectin D1/17-epi-Protectin D1: Authentication and functional regulation of Inflammation-Resolution. <i>Biochemical Pharmacology</i> , 2022, 203, 115181.	2.0	6
11	Maresin 1, a specialized proresolving mediator, stimulates intracellular [Ca ²⁺] _i and secretion in conjunctival goblet cells. <i>Journal of Cellular Physiology</i> , 2021, 236, 340-353.	2.0	10
12	NPD1 rapidly targets mitochondria-mediated apoptosis after acute injection protecting brain against ischemic injury. <i>Experimental Neurology</i> , 2021, 335, 113495.	2.0	13
13	Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 626-628.	2.7	51
14	Carcinogenesis: Failure of resolution of inflammation?. , 2021, 218, 107670.		101
15	Stereoselective Synthesis and Structural Confirmation of the Specialized Pro-Resolving Mediator Resolvin E4. <i>Journal of Organic Chemistry</i> , 2021, 86, 3535-3545.	1.7	15
16	The need for precision nutrition, genetic variation and resolution in Covid-19 patients. <i>Molecular Aspects of Medicine</i> , 2021, 77, 100943.	2.7	23
17	Cysteinyl-specialized proresolving mediators link resolution of infectious inflammation and tissue regeneration via TRAF3 activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	18
18	Pro-Resolving Mediator Annexin A1 Regulates Intracellular Ca ²⁺ and Mucin Secretion in Cultured Goblet Cells Suggesting a New Use in Inflammatory Conjunctival Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 618653.	2.2	12

#	ARTICLE	IF	CITATIONS
19	Bang and Dyerberg's omega-3 discovery turns fifty. <i>Nature Food</i> , 2021, 2, 303-305.	6.2	10
20	Pro-resolving lipid mediator lipoxin A4 attenuates neuro-inflammation by modulating T cell responses and modifies the spinal cord lipidome. <i>Cell Reports</i> , 2021, 35, 109201.	2.9	30
21	PCTR1 Enhances Repair and Bacterial Clearance in Skin Wounds. <i>American Journal of Pathology</i> , 2021, 191, 1049-1063.	1.9	10
22	Formylpeptide receptors in GtoPdb v.2021.2. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2021, 2021, .	0.2	1
23	Protectins PCTR1 and PD1 Reduce Viral Load and Lung Inflammation During Respiratory Syncytial Virus Infection in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 704427.	2.2	21
24	Resolution of inflammation: An organizing principle in biology and medicine. , 2021, 227, 107879.		137
25	A new synthetic protectin D1 analog 3-oxa-PD1_{n-3} DPA</sub> reduces neuropathic pain and chronic itch in mice. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 2744-2752.	1.5	9
26	Neuroprotectin <sc>D1</sc> Attenuates Blast Overpressure Induced Reactive Microglial Cells in the Cochlea. <i>Laryngoscope</i> , 2021, 131, E2018-E2025.	1.1	2
27	Sex Hormone-Dependent Lipid Mediator Formation in Male and Female Mice During Peritonitis. <i>Frontiers in Pharmacology</i> , 2021, 12, 818544.	1.6	5
28	Human leukocytes selectively convert 4<i>S</i>,5<i>S</i>-epoxy-resolvin to resolvin D3, resolvin D4, and a cys-resolvin isomer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
29	Nutrients and Gene Expression in Inflammation. , 2020, , 457-467.		0
30	Cysteinyl maresins regulate the proinflammatory lung actions of cysteinyl leukotrienes. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 335-344.	1.5	38
31	Stereoselective synthesis of MaR2n-3 DPA. <i>Tetrahedron Letters</i> , 2020, 61, 151510.	0.7	5
32	Lack of resolution sensor drives age-related cardiometabolic and cardiorenal defects and impedes inflammation-resolution in heart failure. <i>Molecular Metabolism</i> , 2020, 31, 138-149.	3.0	43
33	The Atlas of Inflammation Resolution (AIR). <i>Molecular Aspects of Medicine</i> , 2020, 74, 100894.	2.7	110
34	Acute injection of a DHA triglyceride emulsion after hypoxic-ischemic brain injury in mice increases both DHA and EPA levels in blood and brain. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2020, 162, 102176.	1.0	7
35	D-series Resolvins activate Phospholipase D in phagocytes during inflammation and resolution. <i>FASEB Journal</i> , 2020, 34, 15888-15906.	0.2	13
36	Staphylococcus aureus-Derived β -Hemolysin Evokes Generation of Specialized Pro-resolving Mediators Promoting Inflammation Resolution. <i>Cell Reports</i> , 2020, 33, 108247.	2.9	47

#	ARTICLE	IF	CITATIONS
37	Deficit of resolution receptor magnifies inflammatory leukocyte directed cardiorenal and endothelial dysfunction with signs of cardiomyopathy of obesity. <i>FASEB Journal</i> , 2020, 34, 10560-10573.	0.2	13
38	Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 337-340.	2.7	169
39	Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. <i>Haematologica</i> , 2020, 105, 2056-2070.	1.7	70
40	RvE1 uses the LTB4 receptor BLT1 to increase [Ca ²⁺] _i and stimulate mucin secretion in cultured rat and human conjunctival goblet cells. <i>Ocular Surface</i> , 2020, 18, 470-482.	2.2	12
41	Resolvin E1 Reduces Leukotriene B ₄ -Induced Intracellular Calcium Increase and Mucin Secretion in Rat Conjunctival Goblet Cells. <i>American Journal of Pathology</i> , 2020, 190, 1823-1832.	1.9	10
42	Molecular and Cellular Differences in Cardiac Repair of Male and Female Mice. <i>Journal of the American Heart Association</i> , 2020, 9, e015672.	1.6	46
43	A New E-Series Resolvin: RvE4 Stereochemistry and Function in Efferocytosis of Inflammation-Resolution. <i>Frontiers in Immunology</i> , 2020, 11, 631319.	2.2	33
44	Specialized pro-resolving mediator network: an update on production and actions. <i>Essays in Biochemistry</i> , 2020, 64, 443-462.	2.1	231
45	Pro-Resolving Lipid Mediators and Anti-Angiogenic Therapy Exhibit Synergistic Anti-Tumor Activity via Resolvin Receptor Activation. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	4
46	Leukotriene receptors (version 2020.3) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2020, 2020, .	0.2	0
47	Vacuolar (H ⁺)-ATPase Critically Regulates Specialized Proresolving Mediator Pathways in Human M2-like Monocyte-Derived Macrophages and Has a Crucial Role in Resolution of Inflammation. <i>Journal of Immunology</i> , 2019, 203, 1031-1043.	0.4	24
48	Resolvin D4 attenuates the severity of pathological thrombosis in mice. <i>Blood</i> , 2019, 134, 1458-1468.	0.6	69
49	Resolvin D5 Inhibits Neuropathic and Inflammatory Pain in Male But Not Female Mice: Distinct Actions of D-Series Resolvins in Chemotherapy-Induced Peripheral Neuropathy. <i>Frontiers in Pharmacology</i> , 2019, 10, 745.	1.6	71
50	Biosynthetic metabolomes of cysteinyl-containing immunoresolvents. <i>FASEB Journal</i> , 2019, 33, 13794-13807.	0.2	20
51	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , 2019, 176, S21-S141.	2.7	519
52	Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5. <i>Science Advances</i> , 2019, 5, eaax0629.	4.7	13
53	Resolution metabolomes activated by hypoxic environment. <i>Science Advances</i> , 2019, 5, eaax4895.	4.7	50
54	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease. <i>Nature Communications</i> , 2019, 10, 3945.	5.8	127

#	ARTICLE	IF	CITATIONS
55	Adipocytes promote ovarian cancer chemoresistance. <i>Scientific Reports</i> , 2019, 9, 13316.	1.6	58
56	Endogenous Specialized Proresolving Mediator Profiles in a Novel Experimental Model of Lymphatic Obstruction and Intestinal Inflammation in African Green Monkeys. <i>American Journal of Pathology</i> , 2019, 189, 1953-1972.	1.9	10
57	Resolvin D2 elevates cAMP to increase intracellular [Ca ²⁺] and stimulate secretion from conjunctival goblet cells. <i>FASEB Journal</i> , 2019, 33, 8468-8478.	0.2	15
58	Aspirin-triggered proresolving mediators stimulate resolution in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6292-6297.	3.3	110
59	Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome. <i>FASEB Journal</i> , 2019, 33, 6140-6153.	0.2	95
60	Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions. <i>Cell Chemical Biology</i> , 2019, 26, 244-254.e4.	2.5	25
61	Novel mediators and mechanisms in the resolution of infectious inflammation: evidence for vagus regulation. <i>Journal of Internal Medicine</i> , 2019, 286, 240-258.	2.7	43
62	Resolution of sickle cell disease-associated inflammation and tissue damage with 17R-resolvin D1. <i>Blood</i> , 2019, 133, 252-265.	0.6	50
63	Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1. <i>Chemistry - A European Journal</i> , 2019, 25, 1476-1480.	1.7	20
64	Resolvin D1, but not resolvin E1, transactivates the epidermal growth factor receptor to increase intracellular calcium and glycoconjugate secretion in rat and human conjunctival goblet cells. <i>Experimental Eye Research</i> , 2019, 180, 53-62.	1.2	10
65	Resolvin D1 treatment on goblet cell mucin and immune responses in the chronic allergic eye disease (AED) model. <i>Mucosal Immunology</i> , 2019, 12, 145-153.	2.7	23
66	Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology. <i>British Journal of Pharmacology</i> , 2019, 176, 1024-1037.	2.7	108
67	Immunoresolvent Resolvin D1 Maintains the Health of the Ocular Surface. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1161, 13-25.	0.8	15
68	Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. <i>Journal of Clinical Investigation</i> , 2019, 129, 2964-2979.	3.9	94
69	Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions. <i>Journal of Clinical Investigation</i> , 2019, 129, 5294-5311.	3.9	158
70	Leukotriene receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	2
71	Synergy between Resolvins and Immune Checkpoint Blockade in a Novel Transplantable FANCC Murine Head and Neck Tumor Model. <i>FASEB Journal</i> , 2019, 33, 496.10.	0.2	1
72	Formylpeptide receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	0

#	ARTICLE	IF	CITATIONS
73	A tribute to Gerald Weissmann (1930–2019). <i>Journal of Clinical Investigation</i> , 2019, 129, 4553-4555.	3.9	0
74	Resolvin D3 multi-level proresolving actions are host protective during infection. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2018, 138, 81-89.	1.0	51
75	Splenic leukocytes define the resolution of inflammation in heart failure. <i>Science Signaling</i> , 2018, 11, .	1.6	90
76	15-epi-Lipoxin A4, Resolvin D2, and Resolvin D3 Induce NF- κ B Regulators in Bacterial Pneumonia. <i>Journal of Immunology</i> , 2018, 200, 2757-2766.	0.4	63
77	Identification of proresolving and inflammatory lipid mediators in human psoriasis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1047-1060.	0.6	38
78	Frontline Science: Structural insights into Resolvin D4 actions and further metabolites via a new total organic synthesis and validation. <i>Journal of Leukocyte Biology</i> , 2018, 103, 995-1010.	1.5	28
79	<i>Trypanosoma cruzi</i> Produces the Specialized Proresolving Mediators Resolvin D1, Resolvin D5, and Resolvin E2. <i>Infection and Immunity</i> , 2018, 86, .	1.0	16
80	Lipid Mediator Metabolomics Via LC-MS/MS Profiling and Analysis. <i>Methods in Molecular Biology</i> , 2018, 1730, 59-72.	0.4	65
81	Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. <i>Nature Communications</i> , 2018, 9, 59.	5.8	211
82	Signaling pathways activated by resolvin E1 to stimulate mucin secretion and increase intracellular Ca ²⁺ in cultured rat conjunctival goblet cells. <i>Experimental Eye Research</i> , 2018, 173, 64-72.	1.2	14
83	Biosynthesis of D-Series Resolvins in Skin Provides Insights into their Role in Tissue Repair. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2051-2060.	0.3	58
84	Identification and Complete Stereochemical Assignments of the New Resolvin Conjugates in Tissue Regeneration in Human Tissues that Stimulate Proresolving Phagocyte Functions and Tissue Regeneration. <i>American Journal of Pathology</i> , 2018, 188, 950-966.	1.9	49
85	Metabololipidomic profiling of functional immunoresolvent clusters and eicosanoids in mammalian tissues. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 553-561.	1.0	28
86	New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. <i>Molecular Aspects of Medicine</i> , 2018, 64, 1-17.	2.7	186
87	Resolvins suppress tumor growth and enhance cancer therapy. <i>Journal of Experimental Medicine</i> , 2018, 215, 115-140.	4.2	200
88	Potent Anti-inflammatory and Pro-resolving Effects of Anabasum in a Human Model of Self-resolving Acute Inflammation. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 675-686.	2.3	52
89	Immunoresolvents signaling molecules at intersection between the brain and immune system. <i>Current Opinion in Immunology</i> , 2018, 50, 48-54.	2.4	23
90	Pro-resolving mediators promote resolution in a human skin model of UV-killed <i>Escherichia coli</i> -driven acute inflammation. <i>JCI Insight</i> , 2018, 3, .	2.3	66

#	ARTICLE	IF	CITATIONS
91	Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain. <i>Neuron</i> , 2018, 100, 1292-1311.	3.8	496
92	Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation. <i>Scientific Reports</i> , 2018, 8, 18050.	1.6	69
93	Cutting Edge: Human Vagus Produces Specialized Proresolving Mediators of Inflammation with Electrical Stimulation Reducing Proinflammatory Eicosanoids. <i>Journal of Immunology</i> , 2018, 201, 3161-3165.	0.4	41
94	Synthesis of protectin D1 analogs: novel pro-resolution and radiotracer agents. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 6818-6823.	1.5	15
95	Distinct Analgesic Actions of DHA and DHA-Derived Specialized Pro-Resolving Mediators on Post-operative Pain After Bone Fracture in Mice. <i>Frontiers in Pharmacology</i> , 2018, 9, 412.	1.6	68
96	Immune responsive resolvin D1 programs myocardial infarction-induced cardiorenal syndrome in heart failure. <i>FASEB Journal</i> , 2018, 32, 3717-3729.	0.2	54
97	New maresin conjugates in tissue regeneration pathway counters leukotriene D ₄ -stimulated vascular responses. <i>FASEB Journal</i> , 2018, 32, 4043-4052.	0.2	35
98	Targeting lipid mediators in cancer biology. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 557-572.	2.7	47
99	Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 9252-9257.	3.3	38
100	The Protectin Family of Specialized Pro-resolving Mediators: Potent Immunoresolvents Enabling Innovative Approaches to Target Obesity and Diabetes. <i>Frontiers in Pharmacology</i> , 2018, 9, 1582.	1.6	77
101	A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS. <i>JCI Insight</i> , 2018, 3, .	2.3	78
102	Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. <i>Journal of Clinical Investigation</i> , 2018, 128, 2657-2669.	3.9	858
103	Lipoxin A4 activates ALX/FPR2 receptor to regulate conjunctival goblet cell secretion. <i>Mucosal Immunology</i> , 2017, 10, 46-57.	2.7	52
104	Identification and Profiling of Specialized Pro-Resolving Mediators in Human Tears by Lipid Mediator Metabolomics. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2017, 117, 17-27.	1.0	99
105	Vagal Regulation of Group 3 Innate Lymphoid Cells and the Immunoresolvent PCTRI Controls Infection Resolution. <i>Immunity</i> , 2017, 46, 92-105.	6.6	122
106	Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. <i>FASEB Journal</i> , 2017, 31, 1273-1288.	0.2	437
107	Plasma lipoxin A ₄ and resolvin D1 are not associated with reduced adenoma risk in a randomized trial of aspirin to prevent colon adenomas. <i>Molecular Carcinogenesis</i> , 2017, 56, 1977-1983.	1.3	20
108	NLRP3 Inflammasome Deficiency Protects against Microbial Sepsis via Increased Lipoxin B ₄ Synthesis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 713-726.	2.5	126

#	ARTICLE	IF	CITATIONS
109	Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. <i>Molecular Aspects of Medicine</i> , 2017, 58, 1-11.	2.7	188
110	Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles: Correlations With Survival and Clinical Outcomes. <i>Critical Care Medicine</i> , 2017, 45, 58-68.	0.4	160
111	The novel lipid mediator PD1n-3 DPA: An overview of the structural elucidation, synthesis, biosynthesis and bioactions. <i>Prostaglandins and Other Lipid Mediators</i> , 2017, 133, 103-110.	1.0	45
112	Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. <i>Molecular Aspects of Medicine</i> , 2017, 58, 114-129.	2.7	255
113	Protectin D1 _{n-3 DPA} and resolvin D5 _{n-3 DPA} are effectors of intestinal protection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3963-3968.	3.3	134
114	Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes. <i>Journal of Immunology</i> , 2017, 198, 718-728.	0.4	69
115	Novel Resolvin D2 Receptor Axis in Infectious Inflammation. <i>Journal of Immunology</i> , 2017, 198, 842-851.	0.4	127
116	Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950â€™Metabolites in Frozen Human Plasma. <i>Journal of Lipid Research</i> , 2017, 58, 2275-2288.	2.0	312
117	ERV1 Overexpression in Myeloid Cells Protects against High Fat Diet Induced Obesity and Glucose Intolerance. <i>Scientific Reports</i> , 2017, 7, 12848.	1.6	36
118	A cluster of immunoresolvents links coagulation to innate host defense in human blood. <i>Science Signaling</i> , 2017, 10, .	1.6	54
119	Atherosclerosis, Periodontal Disease, and Treatment with Resolvins. <i>Current Atherosclerosis Reports</i> , 2017, 19, 57.	2.0	37
120	Specialized Proresolving Mediators Rescue Infant Mice from Lethal <i>Citrobacter rodentium</i> Infection and Promote Immunity against Reinfection. <i>Infection and Immunity</i> , 2017, 85, .	1.0	18
121	Microscale arrays for the profiling of start and stop signals coordinating human-neutrophil swarming. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	74
122	Resolvin D1 Increases Mucin Secretion in Cultured Rat Conjunctival Goblet Cells via Multiple Signaling Pathways. , 2017, 58, 4530.		25
123	Pro-Resolving Mediators in Regulating and Conferring Macrophage Function. <i>Frontiers in Immunology</i> , 2017, 8, 1400.	2.2	120
124	Novel Endogenous Proresolving Molecules:Essential Fatty Acid-Derived and Gaseous Mediators in the Resolution of Inflammation. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 655-664.	0.9	26
125	Identification and Actions of a Novel Third Maresin Conjugate in Tissue Regeneration: MCTR3. <i>PLoS ONE</i> , 2016, 11, e0149319.	1.1	54
126	Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. <i>JCI Insight</i> , 2016, 1, e85922.	2.3	150

#	ARTICLE	IF	CITATIONS
127	Addition of aspirin to a fish oil-rich diet decreases inflammation and atherosclerosis in ApoE-null mice. <i>Journal of Nutritional Biochemistry</i> , 2016, 35, 58-65.	1.9	21
128	Fish Oil Supplementation in Pregnancy. <i>New England Journal of Medicine</i> , 2016, 375, 2599-2601.	13.9	14
129	Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. <i>FASEB Journal</i> , 2016, 30, 2792-2801.	0.2	110
130	Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Protective for Injured Epithelia. <i>American Journal of Pathology</i> , 2016, 186, 1801-1813.	1.9	47
131	Synthesis of 13(<i>R</i>)-Hydroxy-7 <i>Z</i> ,10 <i>Z</i> ,13 <i>R</i> ,14 <i>E</i> ,16 <i>Z</i> ,19 <i>Z</i> -Docosapentaenoic Acid (13 <i>R</i> -HDPA) and Its Biosynthetic Conversion to the 13-Series Resolvins. <i>Journal of Natural Products</i> , 2016, 79, 2693-2702.	1.5	28
132	Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation. <i>Journal of Immunology</i> , 2016, 197, 2362-2368.	0.4	106
133	Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue. <i>Journal of Immunology</i> , 2016, 197, 3360-3370.	0.4	87
134	Lipoxin A4 Counter-regulates Histamine-stimulated Glycoconjugate Secretion in Conjunctival Goblet Cells. <i>Scientific Reports</i> , 2016, 6, 36124.	1.6	27
135	Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. <i>Science Translational Medicine</i> , 2016, 8, 353ra111.	5.8	273
136	Resolvin D4 stereoassignment and its novel actions in host protection and bacterial clearance. <i>Scientific Reports</i> , 2016, 6, 18972.	1.6	81
137	Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12232-12237.	3.3	79
138	Identification and Actions of the Maresin 1 Metabolome in Infectious Inflammation. <i>Journal of Immunology</i> , 2016, 197, 4444-4452.	0.4	64
139	Stretching Impacts Inflammation Resolution in Connective Tissue. <i>Journal of Cellular Physiology</i> , 2016, 231, 1621-1627.	2.0	64
140	Aspirin-triggered resolvin D1 is produced during self-resolving gram-negative bacterial pneumonia and regulates host immune responses for the resolution of lung inflammation. <i>Mucosal Immunology</i> , 2016, 9, 1278-1287.	2.7	81
141	Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase A β 242 Phagocytosis. <i>Molecular Neurobiology</i> , 2016, 53, 2733-2749.	1.9	152
142	The Protectin PCTR1 Is Produced by Human M2 Macrophages and Enhances Resolution of Infectious Inflammation. <i>American Journal of Pathology</i> , 2016, 186, 962-973.	1.9	83
143	Selective identification of specialized pro-resolving lipid mediators from their biosynthetic double di-oxygenation isomers. <i>RSC Advances</i> , 2016, 6, 28820-28829.	1.7	5
144	Human Periodontal Stem Cells Release Specialized Proresolving Mediators and Carry Immunomodulatory and Prohealing Properties Regulated by Lipoxins. <i>Stem Cells Translational Medicine</i> , 2016, 5, 20-32.	1.6	82

#	ARTICLE	IF	CITATIONS
145	Maresin 1 Biosynthesis and Proresolving Anti-infective Functions with Human-Localized Aggressive Periodontitis Leukocytes. <i>Infection and Immunity</i> , 2016, 84, 658-665.	1.0	72
146	Human milk proresolving mediators stimulate resolution of acute inflammation. <i>Mucosal Immunology</i> , 2016, 9, 757-766.	2.7	106
147	Carbon Monoxide Improves Efficacy of Mesenchymal Stromal Cells During Sepsis by Production of Specialized Proresolving Lipid Mediators*. <i>Critical Care Medicine</i> , 2016, 44, e1236-e1245.	0.4	56
148	Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension. <i>JCI Insight</i> , 2016, 1, .	2.3	58
149	Gene Expression of Proresolving Lipid Mediator Pathways Is Associated With Clinical Outcomes in Trauma Patients. <i>Critical Care Medicine</i> , 2015, 43, 2642-2650.	0.4	41
150	Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease. <i>Cell Metabolism</i> , 2015, 22, 125-137.	7.2	170
151	Proresolving Nanomedicines Activate Bone Regeneration in Periodontitis. <i>Journal of Dental Research</i> , 2015, 94, 148-156.	2.5	114
152	The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 53, 314-325.	1.4	56
153	Novel proresolving and tissue-regenerative resolvin and protectin sulfido-conjugated pathways. <i>FASEB Journal</i> , 2015, 29, 2120-2136.	0.2	100
154	Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. <i>Nature Medicine</i> , 2015, 21, 1071-1075.	15.2	215
155	Identification of resolvin D2 receptor mediating resolution of infections and organ protection. <i>Journal of Experimental Medicine</i> , 2015, 212, 1203-1217.	4.2	320
156	Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 84, 24-35.	0.9	194
157	The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. <i>Seminars in Immunology</i> , 2015, 27, 200-215.	2.7	443
158	Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 308, L904-L911.	1.3	62
159	Resolvin D1 Reduces Emphysema and Chronic Inflammation. <i>American Journal of Pathology</i> , 2015, 185, 3189-3201.	1.9	69
160	A mosquito lipoxin/lipocalin complex mediates innate immune priming in <i>Anopheles gambiae</i> . <i>Nature Communications</i> , 2015, 6, 7403.	5.8	73
161	Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L888-L901.	1.3	79
162	Synthesis of the 16 <i>S</i> ,17 <i>S</i> -Epoxyprotectin Intermediate in the Biosynthesis of Protectins by Human Macrophages. <i>Journal of Natural Products</i> , 2015, 78, 2924-2931.	1.5	39

#	ARTICLE	IF	CITATIONS
163	Cutting Edge: Maresin-1 Engages Regulatory T Cells To Limit Type 2 Innate Lymphoid Cell Activation and Promote Resolution of Lung Inflammation. <i>Journal of Immunology</i> , 2015, 194, 863-867.	0.4	155
164	Resolution of inflammation is altered in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 40.	0.4	208
165	Lipid Mediators in the Resolution of Inflammation. <i>Cold Spring Harbor Perspectives in Biology</i> , 2015, 7, a016311.	2.3	389
166	Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 397-413.	1.2	360
167	Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16526-16531.	3.3	144
168	Neuroprotectin/protectin D1: endogenous biosynthesis and actions on diabetic macrophages in promoting wound healing and innervation impaired by diabetes. <i>American Journal of Physiology - Cell Physiology</i> , 2014, 307, C1058-C1067.	2.1	43
169	Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 307, L746-L757.	1.3	36
170	Lipoxin A ₄ modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR ₂ -dependent mechanism. <i>European Journal of Immunology</i> , 2014, 44, 357-369.	1.6	71
171	The Specialized Proresolving Mediator 17-HDHA Enhances the Antibody-Mediated Immune Response against Influenza Virus: A New Class of Adjuvant?. <i>Journal of Immunology</i> , 2014, 193, 6031-6040.	0.4	107
172	Resolution of Acute Inflammation in the Lung. <i>Annual Review of Physiology</i> , 2014, 76, 467-492.	5.6	246
173	Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation. <i>Immunity</i> , 2014, 40, 315-327.	6.6	666
174	Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases. <i>Cell Metabolism</i> , 2014, 19, 21-36.	7.2	378
175	Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E4753-61.	3.3	101
176	Total Synthesis of the Anti-inflammatory and Pro-resolving Lipid Mediator MaR1 ³ DPA Utilizing an sp ³ -sp ³ Negishi Cross-Coupling Reaction. <i>Chemistry - A European Journal</i> , 2014, 20, 14575-14578.	1.7	55
177	The Resolvin D1 Analogue Controls Maturation of Dendritic Cells and Suppresses Alloimmunity in Corneal Transplantation. <i>Investigative Ophthalmology and Visual Science</i> , 2014, 55, 5944.		54
178	Protective Actions of Aspirin-Triggered (17R) Resolvin D1 and Its Analogue, 17R-Hydroxy-19-Fluorophenoxy-Resolvin D1 Methyl Ester, in C5a-Dependent IgG Immune Complex-Induced Inflammation and Lung Injury. <i>Journal of Immunology</i> , 2014, 193, 3769-3778.	0.4	44
179	Synthesis and Anti-inflammatory and Pro-resolving Activities of 22-OH-PD1, a Monohydroxylated Metabolite of Protectin D1. <i>Journal of Natural Products</i> , 2014, 77, 2241-2247.	1.5	39
180	Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. <i>American Journal of Physiology - Cell Physiology</i> , 2014, 307, C39-C54.	2.1	370

#	ARTICLE	IF	CITATIONS
181	Ageing Delays Resolution of Acute Inflammation in Mice: Reprogramming the Host Response with Novel Nano-Proresolving Medicines. <i>Journal of Immunology</i> , 2014, 193, 4235-4244.	0.4	131
182	Total Synthesis of the Lipid Mediator PD1 α -DPA: Configurational Assignments and Anti-inflammatory and Pro-resolving Actions. <i>Journal of Natural Products</i> , 2014, 77, 910-916.	1.5	87
183	Vagus nerve controls resolution and pro-resolving mediators of inflammation. <i>Journal of Experimental Medicine</i> , 2014, 211, 1037-1048.	4.2	143
184	Pro-resolving lipid mediators are leads for resolution physiology. <i>Nature</i> , 2014, 510, 92-101.	13.7	2,266
185	Cutting Edge: Parathyroid Hormone Facilitates Macrophage Efferocytosis in Bone Marrow via Proresolving Mediators Resolvin D1 and Resolvin D2. <i>Journal of Immunology</i> , 2014, 193, 26-29.	0.4	49
186	Update on leukotriene, lipoxin and oxoecosanoid receptors: IUPHAR Review 7. <i>British Journal of Pharmacology</i> , 2014, 171, 3551-3574.	2.7	173
187	P1-099: ALTERED LIPID MEDIATORS AND RECEPTORS OF RESOLUTION IN THE ENTORHINAL CORTEX OF ALZHEIMER'S DISEASE. , 2014, 10, P338-P338.		2
188	Macrophages and the Entrance of Resolution Phase Lipid Mediators. , 2014, , 287-314.		3
189	Maresin Biosynthesis and Identification of Maresin 2, a New Anti-Inflammatory and Pro-Resolving Mediator from Human Macrophages. <i>PLoS ONE</i> , 2014, 9, e102362.	1.1	130
190	Plasma Metabolomics in Human Pulmonary Tuberculosis Disease: A Pilot Study. <i>PLoS ONE</i> , 2014, 9, e108854.	1.1	140
191	Resolution phase lipid mediators of inflammation: agonists of resolution. <i>Current Opinion in Pharmacology</i> , 2013, 13, 632-640.	1.7	272
192	Neuroprotectin/protectin D1 protects against neuropathic pain in mice after nerve trauma. <i>Annals of Neurology</i> , 2013, 74, 490-495.	2.8	102
193	Plasticity of Leukocytic Exudates in Resolving Acute Inflammation Is Regulated by MicroRNA and Proresolving Mediators. <i>Immunity</i> , 2013, 39, 885-898.	6.6	113
194	Unesterified docosahexaenoic acid is protective in neuroinflammation. <i>Journal of Neurochemistry</i> , 2013, 127, 378-393.	2.1	140
195	The resolution of inflammation. <i>Nature Reviews Immunology</i> , 2013, 13, 59-66.	10.6	454
196	Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Potent Immunoresolvents. <i>Chemistry and Biology</i> , 2013, 20, 188-201.	6.2	204
197	Diversity of lipid mediators in human adipose tissue depots. <i>American Journal of Physiology - Cell Physiology</i> , 2013, 304, C1141-C1149.	2.1	112
198	Stereocontrolled Total Synthesis of the Potent Anti-inflammatory and Pro-resolving Lipid Mediator Resolvin D3 and Its Aspirin-Triggered α -Epimer. <i>Organic Letters</i> , 2013, 15, 1424-1427.	2.4	48

#	ARTICLE	IF	CITATIONS
199	Impaired Local Production of Proresolving Lipid Mediators in Obesity and 17-HDHA as a Potential Treatment for Obesity-Associated Inflammation. <i>Diabetes</i> , 2013, 62, 1945-1956.	0.3	181
200	The novel 13 <i>S</i> ,14 <i>S</i> -epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A ₄ hydrolase (LTA ₄ H), and shifts macrophage phenotype. <i>FASEB Journal</i> , 2013, 27, 2573-2583.	0.2	232
201	D-series resolvins attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. <i>FASEB Journal</i> , 2013, 27, 2220-2232.	0.2	112
202	Novel n-3 Immunoresolvents: Structures and Actions. <i>Scientific Reports</i> , 2013, 3, 1940.	1.6	197
203	Resolvin E1 and Chemokine-like Receptor 1 Mediate Bone Preservation. <i>Journal of Immunology</i> , 2013, 190, 689-694.	0.4	115
204	Inhaled Carbon Monoxide Accelerates Resolution of Inflammation via Unique Proresolving Mediator Heme Oxygenase-1 Circuits. <i>Journal of Immunology</i> , 2013, 190, 6378-6388.	0.4	106
205	Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion. <i>Mucosal Immunology</i> , 2013, 6, 1119-1130.	2.7	76
206	Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation. <i>EMBO Molecular Medicine</i> , 2013, 5, 762-775.	3.3	62
207	Contributions of the Three CYP1 Monooxygenases to Pro-Inflammatory and Inflammation-Resolution Lipid Mediator Pathways. <i>Journal of Immunology</i> , 2013, 191, 3347-3357.	0.4	50
208	A Novel Anti-Inflammatory and Pro-Resolving Role for Resolvin D1 in Acute Cigarette Smoke-Induced Lung Inflammation. <i>PLoS ONE</i> , 2013, 8, e58258.	1.1	174
209	Temporal Regulation of Pro-Resolving Mediators and MicroRNA in Self-Limited versus Delayed Resolution of Acute Inflammation. <i>FASEB Journal</i> , 2013, 27, 816.4.	0.2	0
210	Resolvin D1 Receptor Activation Counterregulates H1 histamine receptors in human and rat conjunctival goblet cells. <i>FASEB Journal</i> , 2013, 27, 132.6.	0.2	0
211	Inhaled Carbon Monoxide Accelerates Resolution of Inflammation via Novel Pro-Resolving Mediators and Heme Oxygenase-1. <i>FASEB Journal</i> , 2013, 27, 649.2.	0.2	0
212	Resolvin D1 and Resolvin D5 Lower Antibiotic Doses in Infection. <i>FASEB Journal</i> , 2013, 27, 138.9.	0.2	0
213	Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. <i>Blood</i> , 2012, 120, e60-e72.	0.6	441
214	Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E715-24.	3.3	240
215	Specialized Proresolving Mediators Enhance Human B Cell Differentiation to Antibody-Secreting Cells. <i>Journal of Immunology</i> , 2012, 189, 1036-1042.	0.4	118
216	Moving Beyond "Good Fat, Bad Fat": The Complex Roles of Dietary Lipids in Cellular Function and Health. <i>Advances in Nutrition</i> , 2012, 3, 60-68.	2.9	4

#	ARTICLE	IF	CITATIONS
217	Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. <i>Frontiers in Immunology</i> , 2012, 3, 298.	2.2	118
218	Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 20560-20565.	3.3	91
219	Resolvin D1 and Resolvin D2 Govern Local Inflammatory Tone in Obese Fat. <i>Journal of Immunology</i> , 2012, 189, 2597-2605.	0.4	222
220	Resolution of Inflammation in Asthma. <i>Clinics in Chest Medicine</i> , 2012, 33, 559-570.	0.8	46
221	Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. <i>FASEB Journal</i> , 2012, 26, 1755-1765.	0.2	401
222	Self-Limited versus Delayed Resolution of Acute Inflammation: Temporal Regulation of Pro-Resolving Mediators and MicroRNA. <i>Scientific Reports</i> , 2012, 2, 639.	1.6	102
223	Resolvin D1 Limits Polymorphonuclear Leukocyte Recruitment to Inflammatory Loci. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1970-1978.	1.1	216
224	Resolvin D1 and Aspirin-Triggered Resolvin D1 Promote Resolution of Allergic Airways Responses. <i>Journal of Immunology</i> , 2012, 189, 1983-1991.	0.4	204
225	Resolvin D1 Receptor Stereoselectivity and Regulation of Inflammation and Proresolving MicroRNAs. <i>American Journal of Pathology</i> , 2012, 180, 2018-2027.	1.9	224
226	Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2012, 1821, 1415-1424.	1.2	173
227	Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections. <i>Cell</i> , 2012, 148, 434-446.	13.5	523
228	Resolvin E2 Formation and Impact in Inflammation Resolution. <i>Journal of Immunology</i> , 2012, 188, 4527-4534.	0.4	157
229	Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2012, 87, 127-134.	1.0	34
230	New Lives Given by Cell Death: Macrophage Differentiation Following Their Encounter with Apoptotic Leukocytes during the Resolution of Inflammation. <i>Frontiers in Immunology</i> , 2012, 3, 4.	2.2	163
231	Functional Metabolomics Reveals Novel Active Products in the DHA Metabolome. <i>Frontiers in Immunology</i> , 2012, 3, 81.	2.2	42
232	Infection regulates pro-resolving mediators that lower antibiotic requirements. <i>Nature</i> , 2012, 484, 524-528.	13.7	562
233	Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke. <i>Experimental Neurology</i> , 2012, 236, 122-130.	2.0	98
234	Stereocontrolled total synthesis of Neuroprotectin D1/Protectin D1 and its aspirin-triggered stereoisomer. <i>Tetrahedron Letters</i> , 2012, 53, 1695-1698.	0.7	41

#	ARTICLE	IF	CITATIONS
235	Chemical Mediators of Inflammation and Resolution in Post-Operative Abdominal Aortic Aneurysm Patients. <i>Inflammation</i> , 2012, 35, 98-113.	1.7	49
236	MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. <i>FASEB Journal</i> , 2011, 25, 544-560.	0.2	276
237	International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions. <i>Pharmacological Reviews</i> , 2011, 63, 539-584.	7.1	134
238	Endogenous Anti-inflammatory and Proresolving Lipid Mediators in Renal Disease. , 2011, , 69-92.		2
239	Resolving TRPV1- and TNF-Î±-Mediated Spinal Cord Synaptic Plasticity and Inflammatory Pain with Neuroprotectin D1. <i>Journal of Neuroscience</i> , 2011, 31, 15072-15085.	1.7	207
240	The resolution of inflammation: the devil in the flask and in the details. <i>FASEB Journal</i> , 2011, 25, 1441-1448.	0.2	171
241	Specialized pro-resolving mediators: wiring the circuitry of effector immune and tissue homeostasis. <i>Endodontic Topics</i> , 2011, 24, 39-58.	0.5	8
242	CHARLES N. SERHAN, PHD, The Simon Gelman Professor of Anaesthesia, Director, Center for Experimental Therapeutics & Reperfusion Injury, Professor, Department of Oral Medicine, Infection & Immunity, Department of Biochemistry & Molecular Pharmacology, Harv. <i>Endodontic Topics</i> , 2011, 24, 153-153.	0.5	0
243	Resolvins and Protectins in Inflammation Resolution. <i>Chemical Reviews</i> , 2011, 111, 5922-5943.	23.0	823
244	Metabolomics&Lipidomics of Eicosanoids and Docosanoids Generated by Phagocytes. <i>Current Protocols in Immunology</i> , 2011, 95, Unit 14.26.	3.6	88
245	Chiral lipidomics of E-series resolvins: Aspirin and the biosynthesis of novel mediators. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2011, 1811, 737-747.	1.2	47
246	Emerging roles of resolvins in the resolution of inflammation and pain. <i>Trends in Neurosciences</i> , 2011, 34, 599-609.	4.2	298
247	The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2011, 84, 43-50.	1.0	43
248	Enduring prevention and transient reduction of postoperative pain by intrathecal resolvin D1. <i>Pain</i> , 2011, 152, 557-565.	2.0	94
249	Regulation of inflammation in cancer by eicosanoids. <i>Prostaglandins and Other Lipid Mediators</i> , 2011, 96, 27-36.	1.0	280
250	Novel Proresolving Aspirin-Triggered DHA Pathway. <i>Chemistry and Biology</i> , 2011, 18, 976-987.	6.2	145
251	Antimicrobial Aspects of Inflammatory Resolution in the Mucosa: A Role for Proresolving Mediators. <i>Journal of Immunology</i> , 2011, 187, 3475-3481.	0.4	57
252	Saturated&efferoctosis generates pro-resolving CD11b^{low} macrophages: Modulation by resolvins and glucocorticoids. <i>European Journal of Immunology</i> , 2011, 41, 366-379.	1.6	238

#	ARTICLE	IF	CITATIONS
253	17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live <i>E. coli</i> . <i>Journal of Leukocyte Biology</i> , 2011, 90, 459-470.	1.5	51
254	Lipid Signatures of Unstable Atheromas. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 215-217.	5.1	5
255	Conjunctival Goblet Cell Secretion Stimulated by Leukotrienes Is Reduced by Resolvins D1 and E1 To Promote Resolution of Inflammation. <i>Journal of Immunology</i> , 2011, 186, 4455-4466.	0.4	106
256	Nutrigenetic Disruption of Inflammation-Resolution Homeostasis and Atherogenesis. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2011, 4, 12-24.	1.8	37
257	Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. <i>Biochemical Journal</i> , 2011, 437, 185-197.	1.7	125
258	Decoding Functional Metabolomics with Docosahexaenoyl Ethanolamide (DHEA) Identifies Novel Bioactive Signals. <i>Journal of Biological Chemistry</i> , 2011, 286, 31532-31541.	1.6	79
259	Cutting Edge: Humanized Nano-Proresolving Medicines Mimic Inflammation-Resolution and Enhance Wound Healing. <i>Journal of Immunology</i> , 2011, 186, 5543-5547.	0.4	185
260	Resolvin D2 Is a Potent Endogenous Inhibitor for Transient Receptor Potential Subtype V1/A1, Inflammatory Pain, and Spinal Cord Synaptic Plasticity in Mice: Distinct Roles of Resolvin D1, D2, and E1. <i>Journal of Neuroscience</i> , 2011, 31, 18433-18438.	1.7	210
261	Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. <i>Journal of Clinical Investigation</i> , 2011, 121, 569-581.	3.9	242
262	Impaired Phagocytosis in Localized Aggressive Periodontitis: Rescue by Resolvin E1. <i>PLoS ONE</i> , 2011, 6, e24422.	1.1	129
263	Novel Anti-Inflammatory-Pro-Resolving Mediators and Their Receptors. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 629-647.	1.0	234
264	Resolution of Acute Inflammation and Wound Healing. , 2010, , 17-27.		2
265	Lipid Mediators in Acute Inflammation and Resolution: Eicosanoids, PAF, Resolvins, and Protectins. , 2010, , 153-174.		10
266	A Novel Genus of Specialized Anti-Inflammatory and Pro-Resolution Lipid Mediators. <i>NeuroImmune Biology</i> , 2010, 9, 37-57.	0.2	1
267	Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 87-95.	0.9	143
268	Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. <i>Journal of Internal Medicine</i> , 2010, 268, 15-24.	2.7	80
269	Lipoxins and Aspirin-Triggered 15-epi-Lipoxins. , 2010, , 1235-1242.		0
270	Resolvin E1 Regulates Adenosine Diphosphate Activation of Human Platelets. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 2005-2013.	1.1	96

#	ARTICLE	IF	CITATIONS
271	Resolvin D1 binds human phagocytes with evidence for proresolving receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 1660-1665.	3.3	638
272	Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis. <i>Journal of Biological Chemistry</i> , 2010, 285, 3451-3461.	1.6	234
273	Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. <i>FASEB Journal</i> , 2010, 24, 906-915.	0.2	86
274	Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. <i>Mucosal Immunology</i> , 2010, 3, 270-279.	2.7	90
275	Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. <i>Nature Medicine</i> , 2010, 16, 592-597.	15.2	503
276	Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1. <i>Journal of Lipid Research</i> , 2010, 51, 2018-2031.	2.0	113
277	Specialized pro-resolving lipid mediators in the inflammatory response: An update. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 1260-1273.	1.2	360
278	Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2010, 82, 27-34.	1.0	92
279	Aspirin-Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral Atherosclerosis. <i>American Journal of Pathology</i> , 2010, 177, 2116-2123.	1.9	178
280	Novel Lipid Mediators and Resolution Mechanisms in Acute Inflammation. <i>American Journal of Pathology</i> , 2010, 177, 1576-1591.	1.9	372
281	Novel Lipid Mediators Promote Resolution of Acute Inflammation. <i>Circulation Research</i> , 2010, 107, 1170-1184.	2.0	338
282	International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family. <i>Pharmacological Reviews</i> , 2009, 61, 119-161.	7.1	677
283	Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. <i>FASEB Journal</i> , 2009, 23, 1503-1509.	0.2	42
284	15-Epi-lipoxin A ₄ Inhibits Myeloperoxidase Signaling and Enhances Resolution of Acute Lung Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 311-319.	2.5	199
285	Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. <i>Journal of Experimental Medicine</i> , 2009, 206, 15-23.	4.2	746
286	Anti-angiogenesis Effect of the Novel Anti-inflammatory and Pro-resolving Lipid Mediators. , 2009, 50, 4743.		137
287	Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 44-48.	1.9	138
288	Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. <i>Nature</i> , 2009, 461, 1287-1291.	13.7	599

#	ARTICLE	IF	CITATIONS
289	Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress. <i>British Journal of Pharmacology</i> , 2009, 158, 1062-1073.	2.7	79
290	Anti-inflammatory and pro-resolving properties of benzo-lipoxin A4 analogs. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2009, 81, 357-366.	1.0	51
291	Aspirin-triggered lipoxins override the apoptosis-delaying action of myeloperoxidase in human neutrophils. <i>FASEB Journal</i> , 2009, 23, 739.3.	0.2	0
292	Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography/electrospray ionisation tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 75-83.	0.7	127
293	Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake. <i>American Journal of Hematology</i> , 2008, 83, 437-445.	2.0	67
294	Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1382-1387.	1.0	56
295	An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. <i>British Journal of Pharmacology</i> , 2008, 155, 1214-1223.	2.7	110
296	Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. <i>British Journal of Pharmacology</i> , 2008, 153, S200-15.	2.7	360
297	Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. <i>Nature Reviews Immunology</i> , 2008, 8, 349-361.	10.6	2,492
298	Novel lipid mediators in resolution and their aspirin triggered epimers: Lipoxins, resolvins, and protectins. , 2008, , 93-117.		2
299	Anti-Inflammatory and Proresolving Lipid Mediators. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2008, 3, 279-312.	9.6	422
300	Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2008, 79, 157-163.	1.0	81
301	Resolvin E1 regulates interleukin 23, interferon- γ and lipoxin A4 to promote the resolution of allergic airway inflammation. <i>Nature Immunology</i> , 2008, 9, 873-879.	7.0	384
302	Controlling the Resolution of Acute Inflammation: A New Genus of Dual Anti-inflammatory and Proresolving Mediators. <i>Journal of Periodontology</i> , 2008, 79, 1520-1526.	1.7	97
303	Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. <i>Journal of Experimental Medicine</i> , 2008, 205, 2791-2801.	4.2	325
304	Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. <i>FASEB Journal</i> , 2008, 22, 3595-3606.	0.2	378
305	Tonic inhibition of chemotaxis in human plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17949-17954.	3.3	44
306	Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. <i>Journal of Experimental Medicine</i> , 2008, 205, 1077-1086.	4.2	46

#	ARTICLE	IF	CITATIONS
307	Rapid Appearance of Resolvin Precursors in Inflammatory Exudates: Novel Mechanisms in Resolution. <i>Journal of Immunology</i> , 2008, 181, 8677-8687.	0.4	220
308	Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. <i>Blood</i> , 2008, 112, 848-855.	0.6	204
309	Resolvin E1 Metabolome in Local Inactivation during Inflammation-Resolution. <i>Journal of Immunology</i> , 2008, 180, 3512-3519.	0.4	101
310	Anesthetics Impact the Resolution of Inflammation. <i>PLoS ONE</i> , 2008, 3, e1879.	1.1	101
311	Aspirin-Triggered Lipoxins Override the Apoptosis-Delaying Action of Serum Amyloid A in Human Neutrophils: A Novel Mechanism for Resolution of Inflammation. <i>Journal of Immunology</i> , 2007, 179, 616-622.	0.4	128
312	Resolvin D1 and Its Aspirin-triggered 17R Epimer. <i>Journal of Biological Chemistry</i> , 2007, 282, 9323-9334.	1.6	452
313	Protectin D1 Is Generated in Asthma and Dampens Airway Inflammation and Hyperresponsiveness. <i>Journal of Immunology</i> , 2007, 178, 496-502.	0.4	311
314	Resolvin E1 Regulates Inflammation at the Cellular and Tissue Level and Restores Tissue Homeostasis In Vivo. <i>Journal of Immunology</i> , 2007, 179, 7021-7029.	0.4	392
315	Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing. <i>Journal of Experimental Medicine</i> , 2007, 204, 245-252.	4.2	166
316	Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. <i>FASEB Journal</i> , 2007, 21, 3162-3170.	0.2	193
317	Lipoxin A ₄ stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. <i>FASEB Journal</i> , 2007, 21, 3877-3884.	0.2	102
318	Resolvins and protectins in the termination program of acute inflammation. <i>Trends in Immunology</i> , 2007, 28, 176-183.	2.9	353
319	New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 570-579.	3.2	75
320	Mediator Lipidomics: Search Algorithms for Eicosanoids, Resolvins, and Protectins. <i>Methods in Enzymology</i> , 2007, 432, 275-317.	0.4	42
321	Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation. <i>Journal of Immunology</i> , 2007, 178, 3912-3917.	0.4	548
322	Resolution of inflammation: state of the art, definitions and terms. <i>FASEB Journal</i> , 2007, 21, 325-332.	0.2	949
323	<i>Candida albicans</i> Modulates Host Defense by Biosynthesizing the Pro-Resolving Mediator Resolvin E1. <i>PLoS ONE</i> , 2007, 2, e1316.	1.1	104
324	Endogenous Receptor Agonists: Resolving Inflammation. <i>Scientific World Journal</i> , The, 2007, 7, 1440-1462.	0.8	41

#	ARTICLE	IF	CITATIONS
325	Resolvin D1, protectin D1, and related docosahexaenoic acid-derived products: Analysis via electrospray/low energy tandem mass spectrometry based on spectra and fragmentation mechanisms. <i>Journal of the American Society for Mass Spectrometry</i> , 2007, 18, 128-144.	1.2	91
326	Identification of endogenous resolvin E1 and other lipid mediators derived from eicosapentaenoic acid via electrospray low-energy tandem mass spectrometry: spectra and fragmentation mechanisms. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 7-22.	0.7	21
327	Increased dietary intake of ω -3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. <i>Nature Medicine</i> , 2007, 13, 868-873.	15.2	633
328	Resolvin E1 and protectin D1 activate inflammation-resolution programmes. <i>Nature</i> , 2007, 447, 869-874.	13.7	1,046
329	Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways. <i>Annual Review of Immunology</i> , 2007, 25, 101-137.	9.5	910
330	Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. <i>FASEB Journal</i> , 2007, 21, A131.	0.2	0
331	RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. <i>FASEB Journal</i> , 2006, 20, 401-403.	0.2	374
332	Cell-Cell Interaction in the Transcellular Biosynthesis of Novel ω -3-Derived Lipid Mediators. , 2006, 341, 227-250.		25
333	The discovery and characterization of the leukotrienes. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 972-976.	1.5	2
334	Lipoxins and new lipid mediators in the resolution of inflammation. <i>Current Opinion in Pharmacology</i> , 2006, 6, 414-420.	1.7	180
335	Lipid Mediator Informatics and Proteomics in Inflammation-Resolution. <i>Scientific World Journal</i> , The, 2006, 6, 589-614.	0.8	31
336	Resolution of inflammation: state of the art, definitions and terms. <i>FASEB Journal</i> , 2006, , 672271.	0.2	4
337	Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. <i>Nature Immunology</i> , 2006, 7, 1209-1216.	7.0	331
338	Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. <i>Nature Medicine</i> , 2006, 12, 330-334.	15.2	286
339	Resolvin E2: Identification and Anti-Inflammatory Actions: Pivotal Role of Human 5-Lipoxygenase in Resolvin E Series Biosynthesis. <i>Chemistry and Biology</i> , 2006, 13, 1193-1202.	6.2	212
340	New mechanism for an old drug Aspirin triggers anti-inflammatory lipid mediators with gender implications. <i>Comprehensive Therapy</i> , 2006, 32, 150-157.	0.2	15
341	Lipid mediator informatics-lipidomics: Novel pathways in mapping resolution. <i>AAPS Journal</i> , 2006, 8, E284-E297.	2.2	26
342	Novel Chemical Mediators in the Resolution of Inflammation: Resolvins and Protectins. <i>Anesthesiology Clinics</i> , 2006, 24, 341-364.	1.4	87

#	ARTICLE	IF	CITATIONS
343	Aspirin Has A Gender-Dependent Impact on Antiinflammatory 15-Epi-Lipoxin A 4 Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, e14-7.	1.1	66
344	Resolvins and protectins: novel lipid mediators in anti-inflammation and resolution. <i>Food Nutrition Research</i> , 2006, 50, 68-78.	0.3	11
345	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. <i>FASEB Journal</i> , 2006, 20, 1097-1108.	0.2	37
346	Anti-Inflammatory Actions of Neuroprotectin D1/Protectin D1 and Its Natural Stereoisomers: Assignments of Dihydroxy-Containing Docosatrienes. <i>Journal of Immunology</i> , 2006, 176, 1848-1859.	0.4	424
347	The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo. <i>Pharmacological Reviews</i> , 2006, 58, 463-487.	7.1	431
348	Melanoma growth is reduced in fat-1 transgenic mice: Impact of omega-6/omega-3 essential fatty acids. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 12499-12504.	3.3	125
349	Metabolic Inactivation of Resolvin E1 and Stabilization of Its Anti-inflammatory Actions. <i>Journal of Biological Chemistry</i> , 2006, 281, 22847-22854.	1.6	139
350	Leukotriene B 4 and lipoxin A 4 are regulatory signals for neural stem cell proliferation and differentiation. <i>FASEB Journal</i> , 2006, 20, 1785-1792.	0.2	124
351	Resolvin D Series and Protectin D1 Mitigate Acute Kidney Injury. <i>Journal of Immunology</i> , 2006, 177, 5902-5911.	0.4	322
352	Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 11276-11281.	3.3	361
353	Lipid mediator informatics-lipidomics: Novel pathways in mapping resolution. , 2006, 8, E284.		14
354	Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2005, 8, 115-121.	1.3	184
355	Novel polyisoprenyl phosphates block phospholipase D and human neutrophil activation in vitro and murine peritoneal inflammation in vivo. <i>British Journal of Pharmacology</i> , 2005, 146, 344-351.	2.7	29
356	Resolution of inflammation: the beginning programs the end. <i>Nature Immunology</i> , 2005, 6, 1191-1197.	7.0	2,060
357	Novel ?? 3-derived local mediators in anti-inflammation and resolution. , 2005, 105, 7-21.		173
358	Mediator lipidomics. <i>Prostaglandins and Other Lipid Mediators</i> , 2005, 77, 4-14.	1.0	68
359	Rainbow trout (<i>Oncorhynchus mykiss</i>) brain cells biosynthesize novel docosahexaenoic acid-derived resolvins and protectinsâ€”Mediator lipidomic analysis. <i>Prostaglandins and Other Lipid Mediators</i> , 2005, 78, 107-116.	1.0	75
360	Mediator-lipidomics: databases and search algorithms for PUFA-derived mediators. <i>Journal of Lipid Research</i> , 2005, 46, 790-802.	2.0	60

#	ARTICLE	IF	CITATIONS
361	A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. <i>Journal of Clinical Investigation</i> , 2005, 115, 2774-2783.	3.9	740
362	Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 7671-7676.	3.3	544
363	A synthetic eicosanoid LX α -mimetic unravels host \times donor interactions in allogeneic BMT \times induced GvHD to reveal an early protective role for host neutrophils. <i>FASEB Journal</i> , 2005, 19, 203-210.	0.2	36
364	Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins. <i>Journal of Immunology</i> , 2005, 174, 4345-4355.	0.4	663
365	The Docosatriene Protectin D1 Is Produced by TH2 Skewing and Promotes Human T Cell Apoptosis via Lipid Raft Clustering. <i>Journal of Biological Chemistry</i> , 2005, 280, 43079-43086.	1.6	213
366	Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. <i>Journal of Experimental Medicine</i> , 2005, 201, 713-722.	4.2	829
367	The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: Novel oxygenase products from ω -3 polyunsaturated fatty acids. <i>Biochemical and Biophysical Research Communications</i> , 2005, 338, 149-157.	1.0	115
368	Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005, 73, 141-162.	1.0	382
369	Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005, 73, 163-177.	1.0	219
370	Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005, 73, 301-321.	1.0	56
371	Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15178-15183.	3.3	252
372	From The Cover: Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 8491-8496.	3.3	701
373	Is C-Reactive Protein an Inflammation Opsonin That Signals Colon Cancer Risk?. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 623.	3.8	14
374	A Molecular Defect in Intracellular Lipid Signaling in Human Neutrophils in Localized Aggressive Periodontal Tissue Damage. <i>Journal of Immunology</i> , 2004, 172, 1856-1861.	0.4	98
375	Interactions Between Lipoxin A4, the Stable Analogue 16-phenoxy-lipoxin A4 and Leukotriene B4 in Cytokine Generation by Human Monocytes. <i>Scandinavian Journal of Immunology</i> , 2004, 60, 249-256.	1.3	10
376	Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. <i>British Journal of Pharmacology</i> , 2004, 143, 43-52.	2.7	124
377	Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. <i>Prostaglandins and Other Lipid Mediators</i> , 2004, 73, 155-172.	1.0	260
378	A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. <i>Histochemistry and Cell Biology</i> , 2004, 122, 305-321.	0.8	151

#	ARTICLE	IF	CITATIONS
379	Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. <i>Lipids</i> , 2004, 39, 1125-1132.	0.7	308
380	The opportunistic pathogen <i>Pseudomonas aeruginosa</i> carries a secretable arachidonate 15-lipoxygenase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2135-2139.	3.3	189
381	Clues for new therapeutics in osteoporosis and periodontal disease: new roles for lipoxygenases?. <i>Expert Opinion on Therapeutic Targets</i> , 2004, 8, 643-652.	1.5	19
382	Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: enterolipins for resolomics. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 69-95.	0.8	85
383	Clues for New Therapeutics in Osteoporosis. <i>New England Journal of Medicine</i> , 2004, 350, 1902-1903.	13.9	6
384	A Stable Aspirin-Triggered Lipoxin A4 Analog Blocks Phosphorylation of Leukocyte-Specific Protein 1 in Human Neutrophils. <i>Journal of Immunology</i> , 2004, 173, 2091-2098.	0.4	60
385	Lipoxins and resolvins: Local mediators in endogenous anti-inflammation and resolution. , 2004, , 169-210.		0
386	Aspirin triggers formation of anti-inflammatory mediators: New mechanism for an old drug. <i>Discovery Medicine</i> , 2004, 4, 470-5.	0.5	14
387	A novel rat lipoxin A4 receptor that is conserved in structure and function. <i>British Journal of Pharmacology</i> , 2003, 139, 89-98.	2.7	86
388	Reduced Inflammation and Tissue Damage in Transgenic Rabbits Overexpressing 15-Lipoxygenase and Endogenous Anti-inflammatory Lipid Mediators. <i>Journal of Immunology</i> , 2003, 171, 6856-6865.	0.4	364
389	COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics?. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2003, 69, 339-343.	1.0	46
390	Resolution of Inflammation: A New Paradigm for the Pathogenesis of Periodontal Diseases. <i>Journal of Dental Research</i> , 2003, 82, 82-90.	2.5	413
391	Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. <i>FASEB Journal</i> , 2003, 17, 652-659.	0.2	174
392	Altered Fatty Acid Composition of Dopaminergic Neurons Expressing β -Synuclein and Human Brains with β -Synucleinopathies. <i>Journal of Biological Chemistry</i> , 2003, 278, 49874-49881.	1.6	160
393	Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 14677-14687.	1.6	872
394	Novel Docosanoids Inhibit Brain Ischemia-Reperfusion-mediated Leukocyte Infiltration and Pro-inflammatory Gene Expression. <i>Journal of Biological Chemistry</i> , 2003, 278, 43807-43817.	1.6	714
395	International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors. <i>Pharmacological Reviews</i> , 2003, 55, 195-227.	7.1	271
396	Success of prostaglandin E2 in structure-function is a challenge for structure-based therapeutics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8609-8611.	3.3	90

#	ARTICLE	IF	CITATIONS
397	Lipoxin A4 and Aspirin-Triggered 15-epi-Lipoxin A4 Inhibit Human Neutrophil Migration: Comparisons Between Synthetic 15 Epimers in Chemotaxis and Transmigration with Microvessel Endothelial Cells and Epithelial Cells. <i>Journal of Immunology</i> , 2003, 170, 2688-2694.	0.4	111
398	Aspirin-Triggered Lipoxin A4 and B4 Analogs Block Extracellular Signal-Regulated Kinase-Dependent TNF- α Secretion from Human T Cells. <i>Journal of Immunology</i> , 2003, 170, 6266-6272.	0.4	182
399	Novel Pathways and Endogenous Mediators in Anti-Inflammation and Resolution. , 2003, 83, 115-145.		34
400	Expression of BPI (bactericidal/permeability-increasing protein) in human mucosal epithelia. <i>Biochemical Society Transactions</i> , 2003, 31, 795-800.	1.6	48
401	Lipoxins and Aspirin-Triggered Lipoxins in Airway Responses. <i>Advances in Experimental Medicine and Biology</i> , 2003, 525, 19-23.	0.8	15
402	Lipoxins and Aspirin-Triggered 15-epi-Lipoxins: Mediators in Anti-inflammation and Resolution. , 2003, , 281-285.		1
403	Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3902-3907.	3.3	271
404	Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF- κ B and AP-1 activation, and IL-8 gene expression in human leukocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13266-13271.	3.3	240
405	The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 1359-1364.	3.3	345
406	Novel Lipid Mediator Regulators of Endothelial Cell Proliferation and Migration: Aspirin-Triggered-15R-Lipoxin A4 and Lipoxin A4. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 385-392.	1.3	163
407	Expression of 5-lipoxygenase in pulmonary artery endothelial cells. <i>Biochemical Journal</i> , 2002, 361, 267-276.	1.7	45
408	Resolvins. <i>Journal of Experimental Medicine</i> , 2002, 196, 1025-1037.	4.2	1,486
409	Lipid-Derived Mediators in Endogenous Anti-Inflammation and Resolution: Lipoxins and Aspirin-Triggered 15-epi-Lipoxins. <i>Scientific World Journal</i> , The, 2002, 2, 169-204.	0.8	64
410	Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. <i>Prostaglandins and Other Lipid Mediators</i> , 2002, 68-69, 433-455.	1.0	169
411	Polysisoprenyl phosphates: natural antiinflammatory lipid signals. <i>Cellular and Molecular Life Sciences</i> , 2002, 59, 729-741.	2.4	14
412	Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. <i>Nature Immunology</i> , 2002, 3, 76-82.	7.0	246
413	Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. <i>Nature Medicine</i> , 2002, 8, 1018-1023.	15.2	346
414	Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. <i>Nature Medicine</i> , 2002, 8, 1296-1302.	15.2	435

#	ARTICLE	IF	CITATIONS
415	Identification of Dual Cyclooxygenase- ϵ Eicosanoid Oxidoreductase Inhibitors: NSAIDs That Inhibit PG-LX Reductase/LTB4 Dehydrogenase. <i>Biochemical and Biophysical Research Communications</i> , 2001, 288, 868-874.	1.0	40
416	Selectivity of Recombinant Human Leukotriene D4, Leukotriene B4, and Lipoxin A4 Receptors with Aspirin-Triggered 15-epi-LXA4 and Regulation of Vascular and Inflammatory Responses. <i>American Journal of Pathology</i> , 2001, 158, 3-9.	1.9	176
417	Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. <i>Brazilian Journal of Medical and Biological Research</i> , 2001, 34, 555-566.	0.7	76
418	Lipid mediator class switching during acute inflammation: signals in resolution. <i>Nature Immunology</i> , 2001, 2, 612-619.	7.0	1,229
419	Novel Antiinflammatory Targets for Asthma. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 24, 658-661.	1.4	32
420	Cutting Edge: Nociceptin Stimulates Neutrophil Chemotaxis and Recruitment: Inhibition by Aspirin-Triggered-15-Epi-Lipoxin A4. <i>Journal of Immunology</i> , 2001, 166, 3650-3654.	0.4	100
421	Aspirin-triggered lipoxin A 4 and lipoxin A 4 up-regulate transcriptional corepressor NAB1 in human neutrophils. <i>FASEB Journal</i> , 2001, 15, 1-18.	0.2	59
422	Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. <i>Journal of Clinical Investigation</i> , 2001, 107, 1481-1489.	3.9	130
423	Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of antiinflammation: emergence of the counterregulatory side. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2001, 49, 177-88.	1.0	14
424	Oxidoreductases in Lipoxin A4 Metabolic Inactivation. <i>Journal of Biological Chemistry</i> , 2000, 275, 25372-25380.	1.6	165
425	Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. <i>European Respiratory Journal</i> , 2000, 16, 44-49.	3.1	171
426	Preventing injury from within, using selective cPLA2 inhibitors. <i>Nature Immunology</i> , 2000, 1, 13-15.	7.0	19
427	Cutting Edge: Lipoxin (LX) A4 and Aspirin-Triggered 15-Epi-LXA4 Block Allergen-Induced Eosinophil Trafficking. <i>Journal of Immunology</i> , 2000, 164, 2267-2271.	0.4	114
428	Activation of Lipoxin a4 Receptors by Aspirin-Triggered Lipoxins and Select Peptides Evokes Ligand-Specific Responses in Inflammation. <i>Journal of Experimental Medicine</i> , 2000, 191, 1197-1208.	4.2	265
429	IMP and AMP deaminase in reperfusion injury down-regulates neutrophil recruitment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 4267-4272.	3.3	45
430	A Synthetic Antagonist for the Peroxisome Proliferator-activated Receptor β Inhibits Adipocyte Differentiation. <i>Journal of Biological Chemistry</i> , 2000, 275, 1873-1877.	1.6	337
431	Formation of Endogenous ϵ Antiinflammatory ϵ Lipid Mediators by Transcellular Biosynthesis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, S95-S101.	2.5	59
432	The Scent of a Phagocyte. <i>Journal of Experimental Medicine</i> , 2000, 192, F5-F8.	4.2	47

#	ARTICLE	IF	CITATIONS
433	Cyclooxygenase-2-Derived Prostaglandin E2 and Lipoxin A4 Accelerate Resolution of Allergic Edema in <i>Angiostrongylus costaricensis</i> -Infected Rats: Relationship with Concurrent Eosinophilia. <i>Journal of Immunology</i> , 2000, 164, 1029-1036.	0.4	126
434	Aspirin triggered lipid mediators: novel inhibitors of leucocyte trafficking. <i>Thorax</i> , 2000, 55, 10S-12.	2.7	4
435	Polyisoprenyl Phosphate Signaling: Topography in Human Neutrophils. <i>Biochemical and Biophysical Research Communications</i> , 2000, 275, 739-745.	1.0	9
436	Lipoxin A4 Analogues Inhibit Leukocyte Recruitment to <i>Porphyromonas gingivalis</i> : A Role for Cyclooxygenase-2 and Lipoxins in Periodontal Disease. <i>Biochemistry</i> , 2000, 39, 4761-4768.	1.2	191
437	Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2 "Nonsteroidal Antiinflammatory Drugs and Transcellular Processing. <i>Journal of Experimental Medicine</i> , 2000, 192, 1197-1204.	4.2	1,048
438	A Novel Polyisoprenyl Phosphate Signaling Cascade in Human Neutrophils. <i>Annals of the New York Academy of Sciences</i> , 2000, 905, 69-80.	1.8	2
439	Local and Systemic Delivery of an Aspirin-Triggered Lipoxin Stable Analog Inhibits Neutrophil Trafficking. <i>Annals of the New York Academy of Sciences</i> , 2000, 905, 274-278.	1.8	11
440	Lipoxins, Aspirin-Triggered 15-epi-Lipoxin Stable Analogs and Their Receptors in Anti-Inflammation: A Window for Therapeutic Opportunity. , 2000, , 143-185.		18
441	Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. <i>Journal of Physiology and Pharmacology</i> , 2000, 51, 643-54.	1.1	61
442	Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a "stop"™ signaling switch for aspirin-triggered lipoxin A ₄ . <i>FASEB Journal</i> , 1999, 13, 903-911.	0.2	104
443	Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A ₄ . <i>American Journal of Physiology - Cell Physiology</i> , 1999, 277, C870-C877.	2.1	46
444	LXA ₄ , aspirin-triggered 15-epi-LXA ₄ , and their analogs selectively downregulate PMN azurophilic degranulation. <i>American Journal of Physiology - Cell Physiology</i> , 1999, 276, C988-C994.	2.1	61
445	Lipoxin and Aspirin-Triggered 15-epi-Lipoxin Cellular Interactions Anti-Inflammatory Lipid Mediators. <i>Clinical Chemistry and Laboratory Medicine</i> , 1999, 37, 299-309.	1.4	31
446	Lipoxin (LX)A4 and Aspirin-triggered 15-epi-LXA4 Inhibit Tumor Necrosis Factor α -initiated Neutrophil Responses and Trafficking: Regulators of a Cytokine-Chemokine Axis. <i>Journal of Experimental Medicine</i> , 1999, 189, 1923-1930.	4.2	202
447	Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 8247-8252.	3.3	221
448	Lipoxin A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor-alpha-initiated neutrophil responses and trafficking: novel regulators of a cytokine-chemokine axis relevant to periodontal diseases. <i>Journal of Periodontal Research</i> , 1999, 34, 370-373.	1.4	41
449	Transcellular Regulation of Eicosanoid Biosynthesis. , 1999, 120, 119-144.		45
450	Aspirin-Triggered 15-Epi-Lipoxin A4 and Novel Lipoxin B4 Stable Analogs Inhibit Neutrophil-Mediated Changes in Vascular Permeability. <i>Advances in Experimental Medicine and Biology</i> , 1999, 469, 287-293.	0.8	22

#	ARTICLE	IF	CITATIONS
451	Update on Arachidonic Acid Cascade. , 1999, , 51-92.		3
452	Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. <i>Journal of Clinical Investigation</i> , 1999, 104, 309-316.	3.9	197
453	Anti-Inflammatory Actions of Lipoxin A4 Stable Analogs Are Demonstrable in Human Whole Blood: Modulation of Leukocyte Adhesion Molecules and Inhibition of Neutrophil-Endothelial Interactions. <i>Blood</i> , 1999, 94, 4132-4142.	0.6	90
454	Anti-inflammatory actions of lipoxin A(4) stable analogs are demonstrable in human whole blood: modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions. <i>Blood</i> , 1999, 94, 4132-42.	0.6	40
455	Identification of a Human Enterocyte Lipoxin A4 Receptor That Is Regulated by Interleukin (IL)-13 and Interferon β and Inhibits Tumor Necrosis Factor α -induced IL-8 Release. <i>Journal of Experimental Medicine</i> , 1998, 187, 1285-1294.	4.2	206
456	Polyisoprenyl phosphates: a novel class of intracellular stop signals in neutrophils. <i>Expert Opinion on Therapeutic Targets</i> , 1998, 2, 27-29.	1.0	1
457	Lipoxin B ₄ regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B ₄ analogs with increased biologic activity. <i>FASEB Journal</i> , 1998, 12, 487-494.	0.2	92
458	Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs. <i>Journal of Clinical Investigation</i> , 1998, 101, 1860-1869.	3.9	147
459	Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. <i>Journal of Clinical Investigation</i> , 1998, 101, 819-826.	3.9	202
460	Characterization of human neutrophil and endothelial cell ligand-operated extracellular acidification rate by microphysiometry: impact of reoxygenation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1998, 285, 252-61.	1.3	23
461	Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1998, 287, 779-90.	1.3	86
462	Lipoxin A4 Stable Analogs Are Potent Mimetics That Stimulate Human Monocytes and THP-1 Cells via a G-protein-linked Lipoxin A4 Receptor. <i>Journal of Biological Chemistry</i> , 1997, 272, 6972-6978.	1.6	237
463	Aspirin-triggered 15-Epi-Lipoxin A4 (LXA4) and LXA4 Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-inflammatory Receptors. <i>Journal of Experimental Medicine</i> , 1997, 185, 1693-1704.	4.2	405
464	Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: Role of P-selectin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 9967-9972.	3.3	104
465	Polyisoprenyl phosphates in intracellular signalling. <i>Nature</i> , 1997, 389, 985-990.	13.7	58
466	Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): A jungle of cell-cell interactions or a therapeutic opportunity?. <i>Prostaglandins</i> , 1997, 53, 107-137.	1.2	234
467	Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions?. <i>Journal of Clinical Investigation</i> , 1997, 99, 1147-1148.	3.9	27
468	Aspirin-Triggered Lipoxins (15-epi-LX) Are Generated by the Human Lung Adenocarcinoma Cell Line (A549) Neutrophil Interactions and Are Potent Inhibitors of Cell Proliferation. <i>Molecular Medicine</i> , 1996, 2, 583-596.	1.9	183

#	ARTICLE	IF	CITATIONS
469	Lipid mediator networks in cell signaling: update and impact of cytokines ¹. FASEB Journal, 1996, 10, 1147-1158.	0.2	396
470	Signalling the fat controller. Nature, 1996, 384, 23-24.	13.7	236
471	Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction.. Journal of Experimental Medicine, 1996, 183, 137-146.	4.2	278
472	Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Molecular Medicine, 1996, 2, 583-96.	1.9	74
473	Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. Journal of Immunology, 1996, 156, 2264-72.	0.4	166
474	Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 9475-9479.	3.3	682
475	Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney International, 1995, 47, 1295-1302.	2.6	113
476	Potential vascular roles for lipoxins in the "œstop programs" of host defense and inflammation. Trends in Cardiovascular Medicine, 1995, 5, 186-192.	2.3	19
477	Lipoxin A4 Receptor Activation Is Distinct from That of the Formyl Peptide Receptor in Myeloid Cells: Inhibition of CD11/18 Expression by Lipoxin A4-Lipoxin A4 Receptor Interaction. Biochemistry, 1995, 34, 16678-16686.	1.2	127
478	Leukocyte transmigration, chemotaxis, and oxygenated derivatives of arachidonic acid: when is chirality important?. American Journal of Respiratory Cell and Molecular Biology, 1995, 12, 251-253.	1.4	5
479	Design of Lipoxin A4 Stable Analogs That Block Transmigration and Adhesion of Human Neutrophils. Biochemistry, 1995, 34, 14609-14615.	1.2	309
480	Carrier-mediated transport of lipoxin A4 in human neutrophils. American Journal of Physiology - Cell Physiology, 1994, 267, C1525-C1534.	2.1	19
481	Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor.. Journal of Experimental Medicine, 1994, 180, 253-260.	4.2	425
482	Effects of prostaglandin D2, lipoxins and leukotrienes on sleep and brain temperature of rats. Prostaglandins Leukotrienes and Essential Fatty Acids, 1994, 51, 87-93.	1.0	46
483	Lipoxin biosynthesis and its impact in inflammatory and vascular events. Lipids and Lipid Metabolism, 1994, 1212, 1-25.	2.6	255
484	Lipoxin Biosynthesis by Trout Macrophages Involves the Formation of Epoxide Intermediates. Biochemistry, 1994, 33, 856-863.	1.2	52
485	Lipoxin recognition sites of human neutrophils. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, 1994, 22, 317-26.	0.2	3
486	Eicosanoids in leukocyte function. Current Opinion in Hematology, 1994, 1, 69-77.	1.2	34

#	ARTICLE	IF	CITATIONS
487	Agonist-induced lipoxin A4 generation: Detection by a novel lipoxin A4-ELISA. <i>Lipids</i> , 1993, 28, 1047-1053.	0.7	54
488	Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: Conversion to novel 15-oxo and dihydro products. <i>Biochemistry</i> , 1993, 32, 6313-6319.	1.2	104
489	Lipoxin synthase activity of human platelet 12-lipoxygenase. <i>Biochemical Journal</i> , 1993, 296, 127-133.	1.7	80
490	Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers.. <i>Journal of Clinical Investigation</i> , 1993, 92, 75-82.	3.9	199
491	Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins.. <i>Journal of Clinical Investigation</i> , 1993, 92, 1572-1579.	3.9	177
492	Induction of functional lipoxin A4 receptors in HL-60 cells. <i>Blood</i> , 1993, 81, 3395-403.	0.6	19
493	Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy.. <i>Circulation</i> , 1992, 86, 56-63.	1.6	189
494	Adhesion promotes transcellular leukotriene biosynthesis during neutrophil-glomerular endothelial cell interactions: Inhibition by antibodies against CD18 and L-selectin. <i>Biochemical and Biophysical Research Communications</i> , 1992, 186, 1307-1314.	1.0	81
495	Lipoxin generation by human megakaryocyte-induced 12-lipoxygenase. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1992, 1133, 223-234.	1.9	40
496	Lipoxin generation by permeabilized human platelets. <i>Biochemistry</i> , 1992, 31, 8269-8277.	1.2	77
497	Renal hemodynamic actions of lipoxins in rats: a comparative physiological study. <i>American Journal of Physiology - Renal Physiology</i> , 1992, 263, F436-F442.	1.3	23
498	Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. <i>Journal of Biological Chemistry</i> , 1992, 267, 16168-76.	1.6	105
499	Characterization of lipoxins by combined gas chromatography and electron-capture negative ion chemical ionization mass spectrometry: Formation of lipoxin A4 by stimulated human whole blood. <i>Biological Mass Spectrometry</i> , 1991, 20, 45-52.	0.5	32
500	Selective incorporation of 15-HETE in phosphatidylinositol: agonist-induced deacylation and transformation of stored HETEs by human neutrophils. <i>Advances in Prostaglandin, Thromboxane, and Leukotriene Research</i> , 1991, 21A, 105-8.	0.2	2
501	Lipoxins: Eicosanoids carrying intra-and intercellular messages. <i>Journal of Bioenergetics and Biomembranes</i> , 1991, 23, 105-122.	1.0	43
502	Lipoxin A4 and lipoxin B4 stimulate the release but not the oxygenation of arachidonic acid in human neutrophils: Dissociation between lipid remodeling and adhesion. <i>Journal of Cellular Physiology</i> , 1990, 143, 512-523.	2.0	67
503	Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 6248-6252.	3.3	165
504	Intravascular filarial parasites elaborate cyclooxygenase-derived eicosanoids.. <i>Journal of Experimental Medicine</i> , 1990, 172, 993-996.	4.2	60

#	ARTICLE	IF	CITATIONS
505	Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils.. Journal of Experimental Medicine, 1990, 172, 1451-1457.	4.2	175
506	[20] High-performance liquid chromatography separation and determination of lipoxins. Methods in Enzymology, 1990, 187, 167-175.	0.4	13
507	Identification of Lipoxin A ₄ and Its Relationship to the Sulfidopeptide Leukotrienes C ₄ , D ₄ , and E ₄ in the Bronchoalveolar Lavage Fluids Obtained from Patients with Selected Pulmonary Diseases. The American Review of Respiratory Disease, 1990, 141, 1453-1458.	2.9	142
508	Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro.. Journal of Clinical Investigation, 1990, 85, 772-780.	3.9	263
509	Lipoxin formation: evaluation of the role and actions of leukotriene A4. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, 1990, 20, 54-62.	0.2	4
510	15-Hydroxyeicosatetraenoic Acid Inhibits Superoxide Anion Generation by Human Neutrophils: Relationship to Lipoxin Production. Free Radical Research Communications, 1989, 7, 341-345.	1.8	15
511	Human Red Cells Enhance the Formation of 5-Lipoxygenase-Derived Products by Neutrophils. Free Radical Research Communications, 1989, 7, 335-339.	1.8	3
512	On the relationship between leukotriene and lipoxin production by human neutrophils: evidence for differential metabolism of 15-HETE and 5-HETE. Lipids and Lipid Metabolism, 1989, 1004, 158-168.	2.6	76
513	Phospholipid bilayers enhance the stability of leukotriene A4 and epoxytetraenes: Stabilization of eicosanoids by liposomes. Biochemical and Biophysical Research Communications, 1989, 159, 477-481.	1.0	41
514	Lipoxins stimulate prostacyclin generation by human endothelial cells. FEBS Letters, 1989, 245, 167-172.	1.3	80
515	Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 3438-3442.	3.3	142
516	On the generation of lipoxins and novel related compounds by human neutrophils: relationship to leukotriene production. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, 1989, 19, 116-21.	0.2	0
517	Formation of lipoxin A by granulocytes from eosinophilic donors. FEBS Letters, 1987, 217, 242-246.	1.3	78
518	The action of Lipoxin-A on glomerular microcirculatory dynamics in the rat. Biochemical and Biophysical Research Communications, 1987, 145, 408-414.	1.0	55
519	Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science, 1987, 237, 1171-1176.	6.0	2,185
520	Evidence for a 5(6)-epoxytetraene intermediate in the biosynthesis of lipoxins in human leukocytes. FEBS Letters, 1986, 207, 127-132.	1.3	37
521	Lipoxin A. Stereochemistry and biosynthesis.. Journal of Biological Chemistry, 1986, 261, 16340-16345.	1.6	146
522	Lipoxin A. Stereochemistry and biosynthesis. Journal of Biological Chemistry, 1986, 261, 16340-5.	1.6	130

#	ARTICLE	IF	CITATIONS
523	Appearance of an arachidonic acid 15-lipoxygenase pathway upon differentiation of the human promyelocytic cell-line HL-60. FEBS Letters, 1985, 185, 14-18.	1.3	19
524	Formation of leukotriene C4 by human leukocytes exposed to monosodium urate crystals. FEBS Letters, 1984, 167, 109-112.	1.3	7
525	Trihydroxytetraenes: A novel series of compounds formed from arachidonic acid in human leukocytes. Biochemical and Biophysical Research Communications, 1984, 118, 943-949.	1.0	230
526	Formation of leukotrienes and hydroxy acids by human neutrophils and platelets exposed to monosodium urate. Prostaglandins, 1984, 27, 563-581.	1.2	82
527	Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 5335-5339.	3.3	667
528	Inhibition of human natural killer cell activity by (14R,15S)-14,15-dihydroxy-5Z,8Z,10E,12E-icosatetraenoic acid.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 6914-6918.	3.3	32
529	Changes in phosphatidylinositol and phosphatidic acid in stimulated human neutrophils. Biochimica Et Biophysica Acta - Molecular Cell Research, 1983, 762, 420-428.	1.9	94
530	Neutrophil-Endothelial Cell Interactions. , 0, , 141-152.		1
531	Cytokines and Chemokines in Inflammation. , 0, , 175-185.		2
532	Leukocyte Generation of Reactive Oxygen Species. , 0, , 198-207.		0
533	Nonsteroidal Anti-Inflammatory Drugs. , 0, , 234-243.		0
534	Oral Inflammation and Periodontitis. , 0, , 433-447.		0
535	Acute and Chronic Inflammation. , 0, , 1-16.		11
536	Animal Models of Rheumatoid Arthritis. , 0, , 385-412.		2
537	Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases. , 0, , 186-197.		0
538	Cytokines and Chemokines in Inflammation and Cancer. , 0, , 244-252.		1
539	Neural Inflammation, Alzheimer's Disease, and Stroke. , 0, , 259-266.		0
540	Rheumatoid Arthritis/SLE. , 0, , 267-281.		0

#	ARTICLE	IF	CITATIONS
541	Gastrointestinal Inflammation and Ulceration: Mediators of Induction and Resolution. , 0 , 282-298.		0
542	Inflammation in Cardiovascular Diseases. , 0 , 317-328.		0
543	Glomerulonephritis and Ischemia Reperfusion Injury. , 0 , 349-375.		0
544	Ocular Inflammation Models. , 0 , 413-426.		1
545	Atherosclerosis in Experimental Animal Models. , 0 , 427-432.		0
546	Pathogens and Inflammation. , 0 , 448-456.		0
547	Mediators and Mechanisms of Inflammatory Pain. , 0 , 217-233.		0
548	Inflammatory Skin Diseases. , 0 , 299-303.		0
549	Links between Innate and Adaptive Immunity. , 0 , 28-38.		2
550	Cell Adhesion Molecules. , 0 , 208-216.		0
551	Kidney Glomerulonephritis and Renal Ischemia. , 0 , 304-316.		0
552	Neutrophils I. , 0 , 39-48.		0
553	Neutrophils II. , 0 , 49-64.		1
554	Mast Cells as Sentinels of Inflammation. , 0 , 65-73.		0
555	Basophils. , 0 , 74-85.		0
556	Eosinophils. , 0 , 86-95.		0
557	Macrophages. , 0 , 96-106.		0
558	Lymphocytes. , 0 , 107-125.		1

#	ARTICLE	IF	CITATIONS
559	Fibroblasts and Stromal Cells. , 0, , 126-140.		2
560	Models of Acute Inflammation “ Air-Pouch, Peritonitis, and Ischemia-Reperfusion. , 0, , 329-337.		4
561	Lung. , 0, , 253-258.		0
562	Experimental Models of Glomerulonephritis. , 0, , 338-348.		0
563	Roles of Specialized Proresolving Lipid Mediators in Inflammation Resolution and Tissue Repair. , 0, , 1447-1466.		0
564	Novel Anti-Inflammatory and Proresolution Lipid Mediators in Induction and Modulation of Phagocyte Function. , 0, , 265-280.		0